-
公开(公告)号：EP2170956A2
公开(公告)日：2010-04-07
申请号：EP08759230.9
申请日：2008-06-13
发明人： GAST, Daniela , ALTEVOGT, Peter , MOLDENHAUER, Gerhard , BREITLING, Frank , KRÜGER, Achim , WOLTERINK, Silke , LÜTTGAU, Sandra , MÖBIUS, Ulrich , LI, Yi
IPC分类号： C07K16/28
CPC分类号： C07K16/2803 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61N5/02 , A61N5/0613 , A61N5/10 , A61N2005/0661 , A61N2005/1087 , A61N2005/1089 , C07K2317/24 , C07K2317/41 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/30 , G01N33/57492
摘要： The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
-
公开(公告)号：EP1773879A1
公开(公告)日：2007-04-18
申请号：EP05779040.4
申请日：2005-07-27
发明人： ALTEVOGT, Peter , GAST, Daniela , FOGEL, Mina
IPC分类号： C07K14/705 , C12N9/64
CPC分类号： C12N9/6489 , C07K14/70503
摘要： Described is a pharmaceutical composition comprising a compound (s) interfering with the biological activity of L1 and/or ADAM10 or their expression. Also described is the use of said compound (s) for the prevention/treatment of carcinomas like ovarian and endometrial carcinoma. Finally, the diagnosis of highly malignant forms of carcinomas which is based on the determination of the activity/expression of L1 and/or ADAM10 is described.
-
公开(公告)号：EP1773879B1
公开(公告)日：2015-07-08
申请号：EP05779040.4
申请日：2005-07-27
发明人： ALTEVOGT, Peter , KELM, Daniela , FOGEL, Mina
IPC分类号： C07K14/705 , C12N9/64
CPC分类号： C12N9/6489 , C07K14/70503
-
公开(公告)号：EP2170956B1
公开(公告)日：2014-10-22
申请号：EP08759230.9
申请日：2008-06-13
发明人： KELM, Daniela , ALTEVOGT, Peter , MOLDENHAUER, Gerhard , BREITLING, Frank , KRÜGER, Achim , BÄRREITER, Silke , LÜTTGAU, Sandra , MÖBIUS, Ulrich , LI, Yi , SEBENS, Susanne , SCHÄFER, Heiner
CPC分类号： C07K16/2803 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61N5/02 , A61N5/0613 , A61N5/10 , A61N2005/0661 , A61N2005/1087 , A61N2005/1089 , C07K2317/24 , C07K2317/41 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/30 , G01N33/57492
-
5.发明公开
公开(公告)号：EP3200822A1
公开(公告)日：2017-08-09
申请号：EP15770889.2
申请日：2015-09-28
IPC分类号： A61K39/395 , C07K16/28 , A61P35/00 , A61K39/00
CPC分类号： C07K16/2803 , A61K31/277 , A61K31/337 , A61K31/365 , A61K31/407 , A61K31/513 , A61K31/555 , A61K31/704 , A61K31/7048 , A61K33/24 , A61K38/15 , A61K39/39558 , A61K45/06 , A61K47/48561 , A61K2039/505 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/57492
摘要： The present disclosure relates to a binding molecule binding to L1, which is capable of binding to the same L1 epitope recognized by the monoclonal antibody L1-OV52.24, and/or which competes with the monoclonal antibody L1-OV52.24 for binding to L1, wherein the variable part of the light chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 1 or wherein the light chain is encoded by SEQ ID No: 3, and wherein the variable part of the heavy chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 2 or wherein the heavy chain is encoded by SEQ ID No: 4, nucleic acids encoding the binding molecules, uses thereof and pharmaceutical compositions comprising the binding molecules.
摘要翻译： 本公开涉及与L1结合的结合分子，其能够与单克隆抗体L1-OV52.24识别的相同L1表位结合，和/或与单克隆抗体L1-OV52.24竞争结合 L1，其中L1-OV52.24的轻链的可变部分包含根据SEQ ID No：1的序列或其中轻链由SEQ ID No：3编码，并且其中重链的可变部分 L1-OV52.24包含根据SEQ ID No：2的序列或其中重链由SEQ ID No：4编码，编码结合分子的核酸，其用途和包含结合分子的药物组合物。
-
-
-
-
搜索结果
5 条记录 (耗时 0.014 秒)
